Females and Anadrol

Discussion in 'Women and Steroids' started by CensoredBoardsSuck, May 8, 2016.

  1. Would any of the female members that are planning to cycle Anavar soon be willing to substitute A-Bombs instead, and log your results?

    Women usually avoid Anadrol because of it's reputation as a strong compound, but the literature has shown it's probably less likely to cause virilization than Anavar, and personal experience has shown that it induces greater gains.

    Based on Bill Roberts' experience with women using Anadrol, I've recommended 25 mg qd to several women locally. None reported virilization and all were happy with the results and said they would use it again.

    My personal opinion is that Anadrol is a better option for females than Anavar, for several reasons: probably less risk of virilization, better gains, and perhaps most importantly, because it's relatively inexpensive to manufacture, there's less likelihood of a shady source substituting a cheaper, more virilizing steroid in its place.

    Because so few women use it there are almost no logs available so I think it would be beneficial to have several women log their experience here at Meso.

    If any females are interested, I will post studies that compare the risk of virilization with Anavar.
     
  2. Eman

    Eman Member

  3. Devika

    Devika Member AnabolicLab.com Supporter

    Would love to read that info, please!
    I'm trying to figure out what I want to run for my second cycle.
     
  4. Anywhere from 2 to 3 months.
     
  5. I'll post it when I get to a PC. In the meantime, you can read the Bill Roberts stuff here in the articles section here at Meso.
     
    Devika likes this.
  6. Devika

    Devika Member AnabolicLab.com Supporter

    Very interesting read.
    I'll leave it here so other women can read it too:)
    Anadrol - Steroids Profile
     
  7. Happycamper

    Happycamper Member

  8. gr8whitetrukker

    gr8whitetrukker Member AnabolicLab.com Supporter

    What?
    Woman, your confused
    I didn't link that
     
  9. Happycamper

    Happycamper Member

    @Seven Dog did, sorry!
     
  10. gr8whitetrukker

    gr8whitetrukker Member AnabolicLab.com Supporter

    Ur such a biatch:p
     
  11. Millard Baker

    Millard Baker Member

    What are the Best Steroids for Women? by Bill Roberts
     
  12. Devika

    Devika Member AnabolicLab.com Supporter

  13. The first study used 100 - 150mg/d oxymetholone in patients (including women) with advanced human immunodeficiency virus (HIV-1) infection. No signs of virilization were observed.

    The second study involved the use of oxandrolone in combination with GH in girls with Turner syndrome. Signs of virilization were observed at doses of oxandrolone as low as 0.06mg/kg/d or less (roughly 2.5 mg/d for a 100 lbs female).

    From the full text of the oxymethelone study below:

    "All patients tolerated the drug(s) well. Potential side-effects of treatment were increased fatigue (n 2) and impotence (n 1). Peripheral oedema, deep venous thrombosis, hypertension, increased libido or signs of virilization were not observed."

    [Link to full text: http://journals.cambridge.org/download.php?file=/BJN/BJN75_01/S0007114596000165a.pdf&code=f95be3abec9c4864e4a6c55bf429b91c]​


    Br J Nutr.
    1996 Jan;75(1):129-38.
    Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection.
    Hengge UR1, Baumann M, Maleba R, Brockmeyer NH, Goos M.

    Abstract
    The effect of the testosterone derivative oxymetholone alone or in combination with the H1-receptor antagonist ketotifen, which has recently been shown to block tumour necrosis factor alpha (TNF alpha), on weight gain and performance status in human immunodeficiency virus (HIV) patients with chronic cachexia was evaluated in a 30-week prospective pilot study. Thirty patients were randomly assigned to either oxymetholone monotherapy (n 14) or oxymetholone plus ketotifen (n 16). Patients receiving treatment were compared with a group of thirty untreated matched controls, who met the same inclusion criteria. Body weight and the Karnofsky index, which assesses the ability to perform activities of daily life, and several quality-of-life variables were measured to evaluate response to therapy. The average weight gain at peak was 8.2 (SD 6.2) kg (+ 14.5% of body weight at study entry) in the oxymetholone group (P < 0.001), and 6.1 (SD 4.6) kg (+10.9%) in the combination group (P < 0.005), compared with an average weight loss of 1.8 (SD 0.7) kg in the untreated controls. The mean time to peak weight was 19.6 weeks in the monotherapy group and 20.8 weeks in the combination group. The Karnofsky index improved equally in both groups from 56% before to 67% after 20 weeks of treatment (P < 0.05). The quality of life variables (activities of daily life, and appetite/nutrition) improved in 68% (P < 0.05) and 91% (P < 0.01) of the treated patients respectively. Oxymetholone was safe and promoted weight gain in cachectic patients with advanced HIV-1 infection. The addition of ketotifen did not further support weight gain. These results suggest the need for a randomized, double-blind, placebo-controlled multicentre trial.



    J Clin Endocrinol Metab. 2010 Mar;95(3):1151-60.
    Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
    Menke LA1, et al.

    Abstract
    CONTEXT AND OBJECTIVE:
    GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear.

    DESIGN AND PARTICIPANTS:
    A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2) . d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg . d) or conventional (0.06 mg/kg . d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed.

    RESULTS:
    Compared with GH+Pl, GH+Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean +/- sd, 9.5 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 +/- 4.9 vs. 6.8 +/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P < 0.001), adult height gain on GH+Ox 0.06 was not significantly different from that on GH+Pl (8.3 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.3). Breast development was slower on GH+Ox (GH+Ox 0.03, P = 0.02; GH+Ox 0.06, P = 0.05), and more girls reported virilization on GH+Ox 0.06 than on GH+Pl (P < 0.001).

    CONCLUSIONS:
    In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg . d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg . d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development.
     
    tandd6, mands, GearGodess and 3 others like this.
  14. Here's a link to a discussion where BR talks about Anadrol use in females as being a better alternative to traditionally used AAS.

    I suggest everyone give this one a read - it is an excellent discussion.

    Anavar/Primobolan cycle for a female

    I always felt that anadrol got an unfair reputation as being harsh. In reality it seems like anadrol probably has one of the best safety profiles out of the oral AAS. I love the stuff personally.
     
    Devika and CensoredBoardsSuck like this.
  15. Eur J Endocrinol. 2012 Dec 10;168(1):91-9. doi: 10.1530/EJE-12-0404. Print 2013 Jan.
    Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome.
    Freriks K1, et al.

    Abstract

    OBJECTIVE:
    Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by GH treatment. We have previously reported the results of a trial on the effect of oxandrolone (Ox) in girls with TS. Ox in a dose of 0.03 mg/kg per day (Ox 0.03) significantly increased adult height gain, whereas Ox mg/kg per day (0.06) did not, at the cost of deceleration of breast development and mild virilization. The aim of this follow-up study in adult participants of the pediatric trial was to investigate the long-term effects of previous Ox treatment.

    DESIGN AND METHODS:
    During the previous randomized controlled trial, 133 girls were treated with GH combined with placebo (Pl), Ox 0.03, or Ox 0.06 from 8 years of age and estrogen from 12 years. Sixty-eight women (Pl, n=23; Ox 0.03, n=27; and Ox 0.06, n=18) participated in the double-blind follow-up study (mean age, 24.0 years; mean time since stopping GH, 8.7 years; and mean time of Ox/Pl use, 4.9 years). We assessed height, body proportions, breast size, virilization, and body composition.

    RESULTS:
    Height gain (final minus predicted adult height) was maintained at follow-up (Ox 0.03 10.2±4.9 cm, Ox 0.06 9.7±4.4 cm vs Pl 8.0±4.6 cm). Breast size, Tanner breast stage, and body composition were not different between groups. Ox-treated women reported more subjective virilization and had a lower voice frequency.

    CONCLUSION:
    Ox 0.03 mg/kg per day has a beneficial effect on adult height gain in TS patients. Despite previously reported deceleration of breast development during Ox 0.03 treatment, adult breast size is not affected. Mild virilization persists in only a small minority of patients. The long-term evaluation indicates that Ox 0.03 treatment is effective and safe.


    J Voice. 2011 Sep;25(5):602-10.
    The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome.
    Menke LA1, et al.

    Abstract

    OBJECTIVES/HYPOTHESIS:
    Oxandrolone (Ox) increases height gain but may also cause voice deepening in growth hormone (GH)-treated girls with Turner syndrome (TS). We assessed the effect of Ox on objective and subjective speaking voice frequency in GH-treated girls with TS.

    STUDY DESIGN:
    A multicenter, randomized, placebo (Pl)-controlled, double-blind study was conducted.

    METHODS:
    One hundred thirty-three patients were included and treated with GH (1.33 mg/m2/d) from baseline, combined with Pl or Ox in a low (0.03 mg/kg/d) or conventional (0.06 mg/kg/d) dose from the age of 8 years and estrogens from the age of 12 years. Yearly from starting Ox/Pl until 6 months after discontinuing GH+Ox/Pl, voices were recorded and questionnaires were completed.

    RESULTS:
    At start, mean (±standard deviation [SD]) voice frequency SD score (SDS) was high for age (1.0±1.2, P<0.001) but normal for height. Compared with GH+Pl, voices tended to lower on GH+Ox 0.03 (P=0.09) and significantly lowered on GH+Ox 0.06 (P=0.007). At the last measurement, voice frequency SDS was still relatively high in GH+Pl group (0.6±0.7, P=0.002) but similar to healthy girls in both GH+Ox groups. Voice frequency became lower than -2 SDS in one patient (3%) on GH+Ox 0.03 and three patients (11%) on GH+Ox 0.06. The percentage of patients reporting subjective voice deepening was similar between the dosage groups.

    CONCLUSIONS:
    Untreated girls with TS have relatively high-pitched voices. The addition of Ox to GH decreases voice frequency in a dose-dependent way. Although most voice frequencies remain within the normal range, they may occasionally become lower than -2 SDS, especially on GH+Ox 0.06 mg/kg/d.
     
    Devika and Millard Baker like this.
  16. Bill Roberts also mentioned that oxymethlone doesn't affect the menstrual cycle as much as other AAS:

    "Another thing about Anadrol that's remarkable is that other anabolic steroids are very easily disruptive of the menstrual cycle. Even dosages such as 2.5 mg oxandrolone 2x/day commonly raise issues. Anadrol however medically has shown often only moderate effect on the menstrual cycle at 50 mg/day, and in my too-limited experience with it (as I generally don't work with women on steroid cycles) 25 mg/day only lightened and shortened the cycles slightly. Remarkably less disruptive."
    Source: Anavar/Primobolan cycle for a female
     
  17. AIDS. 2003 Mar 28;17(5):699-710.
    Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting.
    Hengge UR1, et al.

    Abstract
    BACKGROUND:
    Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss still remains a serious problem in the care of HIV patients. Various alterations in energy metabolism and endocrine regulation have been found to cause loss of lean body mass (LBM) and body cell mass (BCM). Previous studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of LBM, but these treatments have largely been ineffective in eugonadal individuals.

    STUDY DESIGN:
    Double-blind, randomized, placebo-controlled trial of 89 HIV-positive women and men with wasting assigned to the anabolic steroid oxymetholone [50 mg twice (BID) or three times daily (TID)] or placebo for 16 weeks followed by open-label treatment. STUDY ENDPOINTS: Body weight, bioimpedance measurements, quality of life parameters and appetite.

    RESULTS:
    Oxymetholone led to a significant weight gain of 3.0 +/- 0.5 and 3.5 +/- 0.7 kg in the TID and BID groups, respectively (P < 0.05 for each treatment versus placebo), whereas individuals in the placebo group gained an average of 1.0 +/- 0.7 kg. Body cell mass increased in the oxymetholone BID group (3.8 +/- 0.4 kg; P < 0.0001) and in the oxymetholone TID group (2.1 +/- 0.6 kg; P < 0.005), corresponding to 12.4 and 7.4% of baseline BCM, respectively. Significant improvements were noted in appetite and food intake, increased well-being and reduced weakness by self-examination. The most important adverse event was liver-associated toxicity. Overall, 35% of patients in the TID, 27% of patients in the BID oxymetholone group and no patients in the placebo group had a greater than five times baseline increase for alanine aminotransferase during the double-blind phase of the study.

    CONCLUSIONS:
    Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. The BID (100 mg/day) regimen appeared to be equally effective as the TID (150 mg/day) regimen in terms of weight gain, LBM and BCM and was associated with less, but still significant liver toxicity.
     
    Eman likes this.
  18. Happycamper

    Happycamper Member

    Screenshot_2016-05-08-18-25-22-1.png
     
  19. Devika

    Devika Member AnabolicLab.com Supporter

    Wunderpus and Happycamper like this.
  20. Happycamper

    Happycamper Member

    I like the discussion, mainly @Dr JIM's contribution. None of us are high level competitors or even amateur/novice competitors around here monitored by coaches and physicians so it's good to see a perspective that is rational and with good intentions.
     
    Dr JIM likes this.